BioXell restructures on Phase IIb failure
This article was originally published in Scrip
Executive Summary
Italy's BioXell plans to lay off at least 14 of its 39 employees following a recent decision to terminate the clinical development of its lead product, elocalcitol, a vitamin D3 analogue.